Rakha EAR-FJ, Sasano H, Wu Y. WHO classifcation of tumours editorial board: breast tumours. WHO classifcation of tumours series, 5th ed.; 2019.
Lim SZ, Ong KW, Tan BK, Selvarajan S, Tan PH. Sarcoma of the breast: an update on a rare entity. J Clin Pathol. 2016;69(5):373–81.
Sheth GR, Cranmer LD, Smith BD, Grasso-Lebeau L, Lang JE. Radiation-induced sarcoma of the breast: a systematic review. Oncologist. 2012;17(3):405–18.
Kong J, Shahait AD, Kim S, Choi L. Radiation-induced undifferentiated pleomorphic sarcoma of the breast. BMJ Case Rep. 2020;13(2):e232616
Srinivasamurthy BC, Kulandaivelu AR, Saha K, Saha A. Primary undifferentiated pleomorphic sarcoma of the breast in a young female: a case report. World J Surg Oncol. 2016;14(1):186.
Yamazaki H, Shimizu S, Yoshida T, Suganuma N, Yamanaka T, Yamashita T, Rino Y, Masuda M. A case of undifferentiated pleomorphic sarcoma of the breast with lung and bone metastases. Int J Surg Case Rep. 2018;51:143–6.
Gambichler T, Horny K, Mentzel T, Stricker I, Tannapfel A, Scheel CH, Behle B, Quast DR, Lee YP, Stucker M, et al. Undifferentiated pleomorphic sarcoma of the breast with neoplastic fever: case report and genomic characterization. J Cancer Res Clin Oncol. 2023;149(4):1465–71.
Hartel PH, Bratthauer G, Hartel JV, Fanburg-Smith JC. Primary malignant fibrous histiocytoma (myxofibrosarcoma/pleomorphic sarcoma not otherwise specified) of the breast: clinicopathologic study of 19 cases. Ann Diagn Pathol. 2011;15(6):407–13.
Vera-Sempere F, Llombart-Bosch A. Malignant fibrohistiocytoma (MFH) of the breast. Primary and postirradiation variants – an ultrastructural study. Pathol Res Pract. 1984;178(3):289–96.
Gladdy RA, Qin LX, Moraco N, Edgar MA, Antonescu CR, Alektiar KM, Brennan MF, Singer S. Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas? J Clin Oncol. 2010;28(12):2064–9.
Riad S, Biau D, Holt GE, Werier J, Turcotte RE, Ferguson PC, Griffin AM, Dickie CI, Chung PW, Catton CN, O’sullivan B, Wunder JS. The clinical and functional outcome for patients with radiation-induced soft tissue sarcoma. Cancer. 2012;118(10):2682–92.
Kokkali S, Moreno JD, Klijanienko J, Theocharis S. Clinical and molecular insights of Radiation-Induced breast sarcomas: Is there hope on the Horizon for Effective Treatment of this aggressive disease? Int J Mol Sci. 2022;23(8):4125.
Lei T, Yang Y, Shi Y, Deng X, Peng Y, Wang H, Chen T. Clinicopathological features and genomic profiles of a group of secretory breast carcinomas in which progressive cases have more complex genomic features. Diagn Pathol. 2022;17(1):101.
Mery CM, George S, Bertagnolli MM, Raut CP. Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival. Cancer. 2009;115(18):4055–63.
Hardy TJ, An T, Brown PW, Terz JJ. Postirradiation sarcoma (malignant fibrous histiocytoma) of axilla. Cancer. 1978;42(1):118–24.
Tsuneyoshi M, Enjoji M. Postirradiation sarcoma (malignant fibrous histiocytoma) following breast carcinoma: an ultrastructural study of a case. Cancer. 1979;45(6):1419–23.
Meunier B, Levêque J, Prisé EL,Kerbrat P, Grall JY. Three cases of sarcoma occurring after radiation therapy of breast cancers. Eur J Obstet Gynecol Reprod Biol. 1994;57(1):33–6.
Kirova YM, Vilcoq JR, Asselain B, Sastre-Garau X, Fourquet A. Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. Cancer. 2005;104(4):856–63.
Horii R, Fukuuchi A, Nishi T, Takanashi R. A case of malignant fibrous histiocytoma after breast conserving therapy for breast cancer. Breast Cancer. 2000;7(1):75–7.
Komaei I, Guccione F, Sarra F, Palmeri E, Ieni A, Cardia R, Currò G, Navarra G, Palmeri R. Radiation-induced undifferentiated pleomorphic sarcoma of the breast: a rare but serious complication following breast-conserving therapy. A case report and literature review. G Chir. 2019;40(6):544–50.
Hatta N, Horita Y. Undifferentiated pleomorphic sarcoma in a patient with Cowden syndrome after radiotherapy for breast cancer. J Dermatol. 2019;46(2):e73–5.
Kadouri L, Sagi M, Goldberg Y, Lerer I, Hamburger T, Peretz T. Genetic predisposition to radiation induced sarcoma: possible role for BRCA and p53 mutations. Breast Cancer Res Treat. 2013;140(1):207–11.
Noh JM, Huh SJ, Choi DH, Park W, Nam SJ. Two cases of post-radiation sarcoma after breast cancer treatment. J Breast Cancer. 2012;15(3):364–70.
Quadros CA, Vasconcelos A, Andrade R, Ramos RS, Studart E, Nascimento G, Trajano A. Good outcome after neoadjuvant chemotherapy and extended surgical resection for a large radiation-induced high-grade breast sarcoma. Int Semin Surg Oncol. 2006;3:18.
S M Pierce, A Recht, T I Lingos, A Abner, F Vicini, B Silver, A Herzog, J R Harris. Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer.Int J Radiat Oncol Biol Phys. 1992;23(5):915–23
Joo MW, Kang YK, Ogura K, Iwata S, Kim JH, Jeong WJ, Niu XH, Chinder PS, Kim HS, Seo SW, Chung YG. Post-radiation sarcoma: A study by the Eastern Asian Musculoskeletal Oncology Group. PLOS ONE. 2018;13(10):e0204927.
Cui YY, Han LY, Shang JF, Fang W, Zhao M, Chen D, Liu HG. Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets. Hum Pathol. 2022;123:113–22.
Lesluyes T, Baud J, Perot G, Charon-Barra C, You A, Valo I, Bazille C, Mishellany F, Leroux A, Renard-Oldrini S,Terrier P, Cesne AL, Laé M, Piperno-Neumann S, Sylvie Bonvalot S, Neuville A, Collin F, Maingon P, Coindre JM, Chibon F. Genomic and transcriptomic comparison of post-radiation versus sporadic sarcomas. Mod Pathol. 2019;32(12):1786–94.
Cancer Genome Atlas Research Network. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell. 2017;171(4):950–65.
Thoenen E, Curl A, Iwakuma T. TP53 in bone and soft tissue sarcomas. Pharmacol Ther. 2019;202:149–64.
Ali NM, Niada S, Brini AT, Morris MR, Kurusamy S, Alholle A, Huen D, Antonescu CR, Tirode F, Sumathi V, Latif F. Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone. J Pathol. 2019;247(2):166–76.
Petry V, Bonadio RC, Cagnacci AQC, Senna LAL, Campos RdNG, Cotti GC, Hoff PM, Fragoso MCBV, Estevez-Diz MDP. Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li–Fraumeni syndrome). Familial Cancer. 2020;19(1):47–53.
Knudsen ES, Pruitt SC, Hershberger PA, Witkiewicz AK, Goodrich DW. Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy. Trends Cancer. 2019;5(5):308–24.
Di Fiore R, D’Anneo A, Tesoriere G, Vento R. RB1 in cancer: different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis. J Cell Physiol. 2013;228(8):1676–87.
Widden H, Placzek WJ. The multiple mechanisms of MCL1 in the regulation of cell fate. Commun Biol. 2021;4(1):1029.
Hong AL, Guerriero JL, Doshi MB, Kynnap BD, Kim WJ, Schinzel AC, Modiste R, Schlauch AJ, Adam RM, Kwiatkowski DJ, Beroukhim R, Letai A, Rosenberg JE, Hahn WC. MCL1 and DEDD Promote Urothelial Carcinoma Progression. Mol Cancer Res. 2019;17(6):1294–304.
Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, Metabolism, and Cancer. Cancer Discov. 2015;5(10):1024–39.
Sio TT, Mansfield AS, Grotz TE, Graham RP, Molina JR, Que FG, Miller RC. Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis. J Hum Genet. 2014;59(3):124–8.
Vrana JA, Bieszczad CK, Cleaveland ES, Ma Y, Park JP, Mohandas TK, Craig RW. An MCL1-overexpressing Burkitt lymphoma subline exhibits enhanced survival on exposure to serum deprivation, topoisomerase inhibitors, or staurosporine but remains sensitive to 1-beta-D-arabinofuranosylcytosine. Cancer Res. 2002;62(3):892–900.
Allen TD, Zhu CQ, Jones KD, Yanagawa N, Tsao MS, Bishop JM. Interaction between MYC and MCL1 in the genesis and outcome of non-small-cell lung cancer. Cancer Res. 2011;71(6):2212–21.
Lourenco C, Resetca D, Redel C, Lin P, MacDonald AS, Ciaccio R, Kenney TMG, Wei Y, Andrews DW, Sunnerhagen M, Arrowsmith CH, Raught B, Penn LZ. MYC protein interactors in gene transcription and cancer. Nat Rev Cancer. 2021;21(9):579–91.
Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22–35.
Romieu-Mourez R, Kim DW, Shin SM, Demicco EG, Landesman-Bollag E, Seldin DC, Cardiff RD, Sonenshein GE. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol. 2003;23(16):5738–54.
Morton JP, Sansom OJ. MYC-y mice: from tumour initiation to therapeutic targeting of endogenous MYC. Mol Oncol. 2013;7(2):248–58.
Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, Cidado J, Embrey KJ, Gangl E, Gibbons FD, Gregory GP, Hargreaves D, Hendricks JA, Johannes JW, Johnstone RW, Kazmirski SL, Kettle JG, Lamb ML, Matulis SM, Nooka AK, Packer MJ, Peng B, Rawlins PB, Robbins DW, Schuller AG, Su N, Yang W, Ye Q, Zheng X, Secrist JP, Clark EA, Wilson DM, Fawell SE, Hird AW. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9(1):5341.
Jovanović KK, Roche-Lestienne C, Ghobrial IM, Facon T, Quesnel B, Manier S. Targeting MYC in multiple myeloma. Leukemia. 2018;32(6):1295–306.
Fitzel R, Secker-Grob KA, Keppeler H, Korkmaz F, Schairer R, Erkner E, Schneidawind D, Lengerke C, Hentrich T, Schulze-Hentrich JM, Schneidawind C. Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity. Neoplasia. 2023;41:100902.
Hofvander J, Puls F, Pillay N, Steele CD, Flanagan AM, Magnusson L, Nilsson J, Mertens F. Undiferentiated peomorphic sarcomas with PRDMl0 fusions have a distinct gene expresion profile. J Pathol. 2019;249(4):425–34.
Hofvander J, Tayebwa J, Nilsson J, Magnusson L, Brosjö O, Larsson O, Vult von Steyern F, Mandahl N, Fletcher CD, Mertens F. Recurrent PRDM10 gene fusions in undifferentiated pleomorphic sarcoma. Clin Cancer Res. 2015;21(4):864–9.
Add Comment